References
- Haberland C., Cipriani M., Kucuk O., Sarpel G., Ezdinli E. Z., Ro J. O. Fulminant leukemic polyradiculoneuropathy in a case of B-cell prolymphocytic leukemia. Cancer 1987; 60: 1454–1458
- Symonds R. P., Hogg R. B., Bone I. Paraneoplastic neurological syndromes associated with lymphomas. Leukemia & Lymphoma 1994; 15: 487–490
- Juliusson G., Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2' deoxyadenosine (CdA): relation to opportunistic infections. Blood 1992; 79: 888–894
- Krykowski E., Warzocha K., Robak T. 2-Chlorodeoxyadenosine in the treatment of patients with relapsed chronic lymphocytic leukemia. Archivum Immunologiae et Therapiae Experimentalis. 1995, (in press)
- Saven A., Piro L. D. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Annals of Internal Medicine 1994; 120: 784–791
- Cheson D. D., Vena D. A., Foss F. M., Sorensen J. M. Neurotoxicity of purine analogs: a review. Journal of Clinical Oncology 1994; 12: 2216–2228
- Kobayashi K., Vogelzang N. J., O'Brien S. M., Schilsky R. L., Vokes E. E., Ratain M. J. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer 1994; 74: 168–173
- Spielberger R. T., Larson R. A., O'Brien S. M., Williams S. F., Ratain M. J. Phase I study of 2-chlorodeoxyadenosine (CdA) by 1 hour bolus infusion in hematologic malignancies. Proceedings of the American Society of Clinical Oncology 1993; 12: 140, (abstract 359).
- Vahdat L., Wong E. T., Wile M. J., Rosenblum M., Foley K. M., Warrell R. P. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994; 84: 3429–3434
- Kearns C. M., Blakley R. L., Santana V. M., Crom W. R. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Research 1994; 54: 1235–1239
- Góra-Tybor J., Robak T. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemia L1210 and leukemia P388. Acta Haematologica Polonica 1993; 24: 177–182
- Saven A., Kawasaki H., Carrera C. J., Waltz T., Copeland B., Zyroff J., Kosty M., Carson D. A., Beutler E., Piro L. D. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. Journal of Clinical Oncology 1993; 11: 671–678
- Delannoy A., Hanique G., Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine 1993; 328: 812
- Beutler E., Piro L. D., Saven A., Kay A. C., McMillian R., Longmire R. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leukemia & Lymphomo 1991; 5: 1–8